Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ORTX

Orchard Therapeutics plc ADR

Dec 06 • 04:00PM ET

16.23

Dollar change +0.01
Percentage change 0.03	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.05	Insider Own	1.57%	Shs Outstand	22.73M	Perf Week	0.15%
Market Cap	368.79M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	0.00%	Shs Float	22.37M	Perf Month	2.04%
Income	-72.97M	PEG	-	EPS next Q	-0.13	Inst Own	38.10%	Short Float / Ratio	0.19% / 0.16	Perf Quarter	229.78%
Sales	21.89M	P/S	16.85	EPS this Y	96.16%	Inst Trans	16.08%	Short Interest	0.04M	Perf Half Y	219.39%
Book/sh	1.77	P/B	9.19	EPS next Y	10.29%	ROA	-33.45%	Target Price	16.00	Perf Year	260.72%
Cash/sh	5.52	P/C	2.94	EPS next 5Y	-	ROE	-71.56%	52W Range	3.60 - 16.30	Perf YTD	337.33%
Dividend	-	P/FCF	-	EPS past 5Y	10.62%	ROI	-64.52%	52W High	-0.46%	Beta	0.55
Dividend %	-	Quick Ratio	2.98	Sales past 5Y	248.26%	Gross Margin	56.91%	52W Low	350.57%	ATR	0.09
Employees	166	Current Ratio	3.12	Sales Q/Q	9.39%	Oper. Margin	-499.72%	RSI (14)	83.72	Volatility	0.20% 0.31%
Optionable	Yes	Debt/Eq	0.60	EPS Q/Q	58.23%	Profit Margin	-333.37%	Rel Volume	0.06	Prev Close	16.22
Shortable	Yes	LT Debt/Eq	0.41	Earnings	Nov 13 BMO	Payout	-	Avg Volume	271.42K	Price	16.23
Recom	3.00	SMA20	0.77%	SMA50	8.90%	SMA200	113.72%	Volume	17,229	Change	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-29-21	Resumed	Cantor Fitzgerald	Overweight	$12 → $9
Nov-16-21	Downgrade	JP Morgan	Neutral → Underweight
Aug-18-21	Downgrade	JP Morgan	Overweight → Neutral
Mar-02-21	Resumed	JP Morgan	Overweight
Mar-02-21	Initiated	Stifel	Buy	$12
Jan-07-21	Initiated	Cantor Fitzgerald	Overweight	$16
Jun-01-20	Resumed	Oppenheimer	Outperform
Sep-17-19	Initiated	Guggenheim	Buy	$31
Sep-05-19	Initiated	Barclays	Overweight
Dec-17-18	Upgrade	Goldman	Neutral → Buy
Nov-26-18	Initiated	Wedbush	Outperform	$25
Nov-26-18	Initiated	JP Morgan	Overweight	$25
Nov-26-18	Initiated	Goldman	Neutral	$18

Show Previous Ratings

Nov-30-23 07:00AM	Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH (GlobeNewswire)
Nov-13-23 11:04AM	Orchard Therapeutics PLC (ORTX) Reports Q3 2023 Earnings and Announces Acquisition by Kyowa Kirin (GuruFocus.com)
07:00AM	Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments (GlobeNewswire)
Oct-31-23 07:39AM	Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength? (Zacks)
Oct-26-23 12:29PM	Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm (PR Newswire)
07:00AM	Loading…
07:00AM	Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023 (GlobeNewswire)
Oct-24-23 07:00AM	Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023 (GlobeNewswire)
Oct-17-23 06:03PM	Moore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law Firm (GlobeNewswire)
Oct-09-23 07:53AM	Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock? (Zacks)
Oct-06-23 07:30AM	Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin (Zacks)
04:41AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains? (Zacks)
Oct-05-23 04:04PM	Highly Rated Biotech Orchard Therapeutics Scores A Takeover, Shares Nearly Double (Investor's Business Daily) +95.95%
11:37AM	Why Orchard Therapeutics Stock Is Soaring Today (Motley Fool)
07:55AM	Why Is Orchard Therapeutics (ORTX) Stock Up 98% Today? (InvestorPlace)
03:35AM	Kyowa Kirin to Acquire Orchard Therapeutics (GlobeNewswire)
05:33AM	Loading…
Sep-27-23 05:33AM	Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar? (Zacks) +7.46%
Sep-20-23 04:36AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-18-23 07:00AM	Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review (GlobeNewswire) +15.61%
Aug-31-23 07:00AM	Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023 (GlobeNewswire)
Aug-15-23 01:46PM	Wall Street Analysts Think Orchard Therapeutics PLC Sponsored ADR (ORTX) Could Surge 365.03%: Read This Before Placing a Bet (Zacks)
Aug-05-23 05:53AM	Orchard Therapeutics plc (NASDAQ:ORTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 07:00AM	Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA (GlobeNewswire)
01:00AM	Pharming Group reports second quarter and first half 2023 financial results (PR Newswire)
Aug-02-23 09:11AM	Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel (GlobeNewswire)
Jul-25-23 07:00AM	Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-05-23 06:25AM	Orchard Therapeutics (NASDAQ:ORTX) shareholders have endured a 90% loss from investing in the stock three years ago (Simply Wall St.)
Jun-26-23 07:00AM	Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital (GlobeNewswire)
May-24-23 07:00AM	Orchard Therapeutics to Present at Stifels Genetic Medicines Day (GlobeNewswire)
May-19-23 01:48PM	Why Orchard Therapeutics Stock Is Trading Higher Today (Benzinga) +7.27%
09:00AM	Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT (GlobeNewswire)
07:00AM	Loading…
May-18-23 07:00AM	Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications (GlobeNewswire)
May-16-23 06:02AM	Orchard Therapeutics First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-15-23 07:00AM	Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA (GlobeNewswire)
May-10-23 09:55AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Now Trades Above Golden Cross: Time to Buy? (Zacks)
May-09-23 07:50AM	There's No Escaping Orchard Therapeutics plc's (NASDAQ:ORTX) Muted Revenues (Simply Wall St.)
May-03-23 07:00AM	Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023 (GlobeNewswire)
Mar-30-23 07:00AM	Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day (GlobeNewswire)
Mar-16-23 06:26AM	Analyst Forecasts For Orchard Therapeutics plc (NASDAQ:ORTX) Are Surging Higher (Simply Wall St.) -10.38%
Mar-13-23 11:51AM	Orchard Therapeutics plc (NASDAQ:ORTX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-11-23 09:06AM	Institutions own 23% of Orchard Therapeutics plc (NASDAQ:ORTX) shares but retail investors control 34% of the company (Simply Wall St.)
Mar-10-23 10:00AM	Orchard Therapeutics Completes ADS Ratio Change (GlobeNewswire) -10.31%
Mar-06-23 06:05AM	Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results (GlobeNewswire) +14.58%
06:00AM	Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million (GlobeNewswire)
Mar-03-23 07:00AM	Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023 (GlobeNewswire)
Mar-01-23 06:01AM	11 High Growth UK Stocks to Buy (Insider Monkey)
Feb-27-23 07:00AM	Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden (GlobeNewswire)
Feb-24-23 07:00AM	Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium (GlobeNewswire) -12.36%
Feb-10-23 07:00AM	Orchard Therapeutics Announces Proposed ADS Ratio Change (GlobeNewswire) -9.68%
Feb-08-23 07:00AM	Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium (GlobeNewswire)
Jan-09-23 07:00AM	Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones (GlobeNewswire) +13.34%
Jan-05-23 07:00AM	Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH (GlobeNewswire) +22.33%
Dec-12-22 07:00AM	Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA (GlobeNewswire) +14.37%
Dec-01-22 07:00AM	Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel) (GlobeNewswire)
Nov-14-22 07:00AM	Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights (GlobeNewswire)
Nov-08-22 07:00AM	Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022 (GlobeNewswire)
Nov-07-22 07:00AM	Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 09:05AM	Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022 (GlobeNewswire)
Oct-10-22 07:00AM	Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas (GlobeNewswire)
Aug-29-22 07:00AM	Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio (GlobeNewswire)
Aug-04-22 07:00AM	Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights (GlobeNewswire)
May-12-22 07:00AM	Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress (GlobeNewswire)
May-10-22 07:00AM	Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond (GlobeNewswire)
May-05-22 07:00AM	Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results (GlobeNewswire) -7.41%
May-02-22 07:00AM	Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany (GlobeNewswire)
Apr-11-22 07:00AM	Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy (GlobeNewswire)
Mar-30-22 12:02PM	Orchard Therapeutics Plans To Seek Strategic Options For Immunodeficiency Programs, Cuts Workforce (Benzinga) -5.13%
07:00AM	Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform (GlobeNewswire)
Mar-24-22 07:00AM	Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results (GlobeNewswire)
Mar-03-22 07:00AM	Orchard Therapeutics to Present at Multiple Investor Conferences in March 2022 (GlobeNewswire) -7.22%
Feb-07-22 07:00AM	Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium 2022 (GlobeNewswire)
Feb-03-22 07:01PM	Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients (GlobeNewswire)
Jan-21-22 07:00AM	Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD (GlobeNewswire) -5.61%
Jan-10-22 07:00AM	Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones (GlobeNewswire)
Jan-04-22 07:00AM	Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.62%
Nov-18-21 07:00AM	Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome (GlobeNewswire)
Nov-08-21 11:59AM	Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment? (Simply Wall St.) +6.45%
07:00AM	Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021 (GlobeNewswire)
Nov-04-21 07:45AM	Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates (GlobeNewswire) -10.19%
Oct-13-21 07:00AM	Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress (GlobeNewswire) +5.39%
Sep-14-21 06:00AM	Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event (GlobeNewswire)
Sep-09-21 07:00AM	Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments (GlobeNewswire)
Sep-08-21 07:00AM	Orchard Therapeutics to Host Virtual R&D Investor Event on Tuesday, September 14, 2021 (GlobeNewswire)
Sep-07-21 07:00AM	Orchard Therapeutics Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-21 07:00AM	Orchard Therapeutics to Present at Multiple Investor Conferences in September 2021 (GlobeNewswire) +11.96%
Aug-09-21 09:06AM	Orchard Therapeutics (NASDAQ:ORTX) Share Prices Have Dropped 37% In The Last Year (Simply Wall St.)
Aug-04-21 07:00AM	Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Jul-27-21 05:36PM	Were Hedge Funds Right About Orchard Therapeutics plc (ORTX)? (Insider Monkey)
Jul-01-21 10:35AM	Orchard Therapeutics, Pharming Ink Development Pact For Gene Therapy (Benzinga)
01:00AM	Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema (GlobeNewswire)
Jun-29-21 11:43AM	Orchard Therapeutics Issues Updates On Gene Therapy Programs (Benzinga) -7.22%
07:00AM	Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs (GlobeNewswire)
May-28-21 08:12PM	Column: State's biotech partner on a stem cell cure ends the project, but that's good news (LA Times)
May-24-21 09:00AM	Column: California's stem cell program found a disease cure, but it's being blocked by a biotech firm (LA Times)
May-13-21 07:00AM	Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates (GlobeNewswire) -9.09%
May-11-21 01:06PM	Orchard Therapeutics Posts Long-Term Data For Gene Therapy In Inherited Immune System Disorder (Benzinga)
06:00AM	Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID (GlobeNewswire)
May-10-21 10:50AM	Here's What Orchard Therapeutics plc's (NASDAQ:ORTX) Shareholder Ownership Structure Looks Like (Simply Wall St.) -5.86%
Apr-28-21 07:01AM	Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (GlobeNewswire)
Mar-07-21 06:59AM	JPMorgan Bets on These 3 Stocks; Sees Over 50% Upside Potential (TipRanks)
Mar-03-21 09:00AM	Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy (Business Wire)

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
THOMAS FRANK E	See Remarks	Mar 10	Option Exercise	0.46	20,000	9,182	92,081	Mar 14 08:30 AM
THOMAS FRANK E	See Remarks	Feb 09	Option Exercise	0.46	20,000	9,182	72,081	Feb 13 08:09 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORTX

Orchard Therapeutics plc ADR

Upgrade your FINVIZ experience